news27 July 2017 | By Sarah Wills (Editorial Assistant: European Pharmaceutical Review)
A new study has assessed the safety, tolerability, and effectiveness of extended-release guanfacine in children 6-17 years of age who have chronic tic disorders including Tourette's disorder.